Voyager Therapeutics, Inc. (VYGR) Operating income 2016–2025
Voyager Therapeutics, Inc. (VYGR) annual operating income history from SEC filings — each fiscal year as reported.
-$131.8MFY2025 · since FY2016: -$41.3M → -$131.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$131.8M | -58.3% |
| FY2024 | -$83.3M | -168.3% |
| FY2023 | $122.0M | +340.0% |
| FY2022 | -$50.8M | +30.9% |
| FY2021 | -$73.6M | -368.8% |
| FY2020 | $27.4M | +153.0% |
| FY2019 | -$51.7M | +43.3% |
| FY2018 | -$91.1M | -26.8% |
| FY2017 | -$71.9M | -74.0% |
| FY2016 | -$41.3M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More VYGR financial trends
VYGR RevenueVYGR Net incomeVYGR Net marginVYGR Gross profitVYGR Gross marginVYGR Operating marginVYGR Operating cash flowVYGR Free cash flowVYGR Capital expendituresVYGR Return on equityVYGR Stock buybacksVYGR Dividends paidVYGR Total assetsVYGR Total liabilitiesVYGR Shareholders’ equityVYGR overview →